Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

3173 - Polymedication in elderly cancer patients treated with chemotherapy

Date

22 Oct 2018

Session

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

Topics

Supportive Care and Symptom Management

Tumour Site

Presenters

Anne-Laure COUDERC

Citation

Annals of Oncology (2018) 29 (suppl_8): viii603-viii640. 10.1093/annonc/mdy300

Authors

A. COUDERC1, F. Correard2, C. Tabele2, E. Nouguerede1, L. Greillier3, F. Duffaud4, P. Auquier5, A. Daumas6, P. Bertault-Peres2, P. Villani1, S. Honore2

Author affiliations

  • 1 Department Of Geriatric And Internal Medicine, Assistance Publique Hopitaux de Marseille, 13009 - Marseille/FR
  • 2 Pharmacy, Assistance Publique Hopitaux de Marseille, 13005 - MARSEILLE/FR
  • 3 Department Of Multidisciplinary Oncology And Therapeutic Innovations, Assistance Publique Hopitaux de Marseille, 13015 - Marseille/FR
  • 4 Department Of Oncology, CHU La Timone Adultes, 13385 - Marseille/FR
  • 5 Public Health Research Unit Ea 3279, Aix marseille Université, 13006 - Marseille/FR
  • 6 Department Of Geriatric And Internal Medicine, Assistance Publique Hopitaux de Marseille, 13005 - Marseille/FR
More

Resources

Abstract 3173

Background

Medication reconciliation (MedRec) including complementary and alternative medicine is considered as an important way to increase the safety of medication use. However, there are few studies in literature showing the impact of an oncogeriatric approach integrating MedRec program in elderly cancer patients (ECP). The objective is to measure the impact of a pharmacogeriatric approach (PGA) on ECP before treatment by chemotherapy.

Methods

A monocentric prospective study was implemented to evaluate the overall survival (OS), rate of readmission hospital (RRH) at 1stand 3rdmonth and Early Discontinuation of active treatment (ED). These variables were analyzed according to number of reviewed drugs in MedRec and geriatric tools of Comprehensive Geriatric Assessment (CGA).

Results

144 patients were received in oncogeriatric consultations between 01/2017 and 10/2017 (mean age was 80.9 ± 5.5 years, 52.1 % were men, 48.6 % had metastatic tumors). Main cancers were lung (31.9 %), gastrointestinal (18.1 %), breast and gynecological (16.7 %). At 1st and 3rdmonth, death rates were 3 % and 12 %; RRH were 11.1 % and 16.3 %. Received treatment was analyzed and 62.5% received systemic treatment after oncogeriatric consultations. Concerning ED at 3rd month, 48 % had prematurely stopped it (because of cancer progression in 14.2 % and infections in 7 %) and 23.6 % reduced dose (because of chemotoxicity in 33 % and geriatric conclusions in 20 %). OS prognostic factors were malnutrition (p = 0.03) and metastatic status (p = 0.05), prognosis factors of early death at 1 month were lymphopenia (p = 0.005) and RRH (p = 0.04), and at 3 months: malnutrition (p = 0.01), ADL dependence (p = 0.03), and RRH (p = 0.01).

Conclusions

To our knowledge, this is the first study evaluating and describing the outcomes of PGA with MedRec and CGA in same time for the ECP. First month death rates and RRH are lower compared to literature in our study. RRH, ADL and nutritional disorder are OS prognostic factors. Full analyzes will be presented during the congress to show the real impact of PGA.

Clinical trial identification

Legal entity responsible for the study

Assistance Publique Hôpitaux de Marseille.

Funding

Has not received any funding.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.